Monitoring prostate cancer (PCa) with appraise the gene expression of PRUNE2, NCAPD3 and ASPA and their connection with age, family history and tumor stage

Abstract

IntroductionA major cause of cancer mortality among men is prostate cancer (PCa). In this survey we tried to find a new way to screening and monitoring PCa patients by specific biomarkers like protein prune homolog 2 (PRUNE2), non-SMC condensing complex subunit D3 (NCAPD3), and aspartoacylase (ASPA). Material and methodsBiopsy-proven PCa of 40 Iranian men were collected from the Shahid Akbar Abadi Hospital during 2018 year. Following a screening to determine their family history of prostate cancer encounter, smoking habit and stages and grades of their PCa by tumor, node, and metastasis staging system (TNM) were done by telephone and check the patient file. In the following, their biomarkers are detected by real-time PCR method. ResultsPursuant to our outcome, there is no correlation between neither smoking habits nor age average of PCa and control groups, significantly (P-value > 0.05). There is a significant decreasing in NCAPD3 and ASPA expression in PCa group, yet we can see an opposite result about PRUNE2 expression (P-value < 0.05). Our investigation showed that 5.7% frequency among all PCa samples, which all of them are both family history and smoking positive, presented T4N1M1. ConclusionsUp and down in expression of biomarkers in patients with prostate cancer, give us a clear perspective of “what will happen next” these patients, but if we want to use these biomarkers instead PSA test, we need more studies and information of PRUNE2, NCAPD3, ASPA and other genes connection to PCa.